Interestingly, in a double-blind, placebo, controlled randomized clinical trial, Sanoobar et al. confirmed that exogenous CoQ10 administration for 12 weeks could reduce IL-6 and TNF-α levels in patients with multiple sclerosis [48]. Here, IL6 is linked to multiple sclerosis.